CSU researchers uncover new drug for drug resistant TB

A new drug has been developed by the University of South Florida’s medical school that can prevent or treat drug-resistant TB in animals.

The team at CSU Medical School is the first to isolate a compound that blocks the development of the bacteria that causes drug-resistance.

The new drug, a compound called dibenzopyrrolizumab, can help treat drug resistance in humans and animals, according to Dr. Sarah M. O’Brien, an associate professor in the school’s School of Medicine.

Othara Medical Sciences, a biomedical research company, is the lead developer of the drug.

“This is a remarkable achievement for the biomedical research community in terms of their ability to create a compound with clinical use potential,” said Dr. O”Brien, who is also an assistant professor in CSU’s School for Biomedical Sciences.

The compound is the third drug in the company’s pipeline to be approved for clinical use in humans.

O`Brien and her team also recently reported the first human-to-human drug transfer from mice to humans.

She said she was surprised by the new drug’s safety and efficacy in humans, especially considering that it’s only in mice.

“Our study showed that this compound is highly effective in treating drug- resistant TB in the mice, but that it also showed efficacy in human patients,” she said.

The study, published online on March 30 in the journal PLOS One, was supported by the National Institutes of Health.

In a previous study published in the same journal, CSU scientists reported that dibuzopyrrolimus (dibuzo) has shown promise in the treatment of drug-refreshing TB in humans with drug-susceptibility.

Oribas said that dizoxazole (zinc sulfate) can be used to treat TB but that there is a lack of effective treatment options.

“We have been looking for a way to use zinc sulfate as an anti-tuberculosis drug for several years, but we haven’t found a way yet,” Oriba said.

“Now we have found a solution.”

The compound’s mechanism of action is similar to that of zilpyrone, another anti-TB drug.

But unlike zilpsyrone’s mechanism, dizoxybenzyl sulfate’s mechanism is different, Oribah said.

Orobas said the compound’s ability to inhibit the bacteria responsible for drug-induced TB is similar, and that it was able to do so in a number of different mouse models.

“It’s very promising,” she added.

The research team also reported in the March 30 journal that difluoroacetic acid (DFA) has been shown to be effective in reducing the development and transmission of TB in animal models.

The drug was previously approved in the U.S. and in Europe for the treatment in humans of tuberculosis.

DFA is used in animal studies to treat tuberculosis and is not approved for human use.

Dr. Robert F. Stemler, a professor of pathology at the University at Buffalo School of Veterinary Medicine and a member of the research team, said the work of O’Reillys lab is important for advancing our understanding of TB.

“For the first time, we can look at TB from a new perspective,” he said.

In addition to Oribachs lab, other members of the team include Dr. D. Michael Fuchs, M.D., associate professor of psychiatry and director of the Center for Biocontainment and Research on TB; Dr. Christopher P. Hodge, M, DPT, professor of medicine at the Baylor College of Medicine; and Dr. David B. Kline, MEd, associate professor and director at the Institute of Psychiatry at the Columbia University Medical Center.

This research was supported in part by the Office of Naval Research, National Institutes, and National Institutes on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences, National Cancer Institute, National Science Foundation, and the National Institute on Drug Abuse.

The findings are featured in the April 12 issue of Science, which will be published online March 30.

For more information on TB, visit the National TB Center at http://www.cdc.gov/ntb/index.htm or follow the Center on Twitter at @cdcntb.

Follow the Center’s TB news on Twitter: http://twitter.com/cdc_ntb or on Facebook at http.facebook.com, www.facebook/ctb.csu.edu, or www.ctbinstitute.org/index/news.php.

Copyright © 2017 The Associated Press.

All rights reserved.

This material may not be published, broadcast, rewritten or redistributed without permission.

Get the latest AP Science stories delivered to your inbox.

Related Post

스폰서 파트너

Best Online Casino » Play Online Blackjack, Free Slots, Roulette : Boe Casino.You can play the favorite 21 Casino,1xBet,7Bit Casino and Trada Casino for online casino game here, win real money! When you start playing with boecasino today, online casino games get trading and offers. Visit our website for more information and how to get different cash awards through our online casino platform.우리카지노 - 【바카라사이트】카지노사이트인포,메리트카지노,샌즈카지노.바카라사이트인포는,2020년 최고의 우리카지노만추천합니다.카지노 바카라 007카지노,솔카지노,퍼스트카지노,코인카지노등 안전놀이터 먹튀없이 즐길수 있는카지노사이트인포에서 가입구폰 오링쿠폰 다양이벤트 진행.카지노사이트 - NO.1 바카라 사이트 - [ 신규가입쿠폰 ] - 라이더카지노.우리카지노에서 안전 카지노사이트를 추천드립니다. 최고의 서비스와 함께 안전한 환경에서 게임을 즐기세요.메리트 카지노 더킹카지노 샌즈카지노 예스 카지노 코인카지노 퍼스트카지노 007카지노 파라오카지노등 온라인카지노의 부동의1위 우리계열카지노를 추천해드립니다.